ICTCAR-TCR Hybrid

N/A

Report date: 2025/03/20 15:35:17

Base Information

Drug NameICTCAR-TCR Hybrid
Drug Alias NameICTCAR-Hybridanti-MAGE-A4 CAR T-cell therapy/TCR T-cell therapy (Innovative Cellular Therapeutics)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionHuman leukocyte antigen modulatorsMelanoma-associated antigen 4 modulators
TargetsMelanoma-associated antigen 4Human leukocyte antigen
Therapy Area/IndicationsUrinary Bladder NeoplasmsLung NeoplasmsColorectal Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesInnovative Cellular Therapeutics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesInnovative Cellular Therapeutics Co Ltd
Inactive CompaniesN/A
Active IndicationsUrinary Bladder NeoplasmsLung NeoplasmsColorectal Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A